Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables turns negative
Q2 FY2026 accounts payables was -$7M, compared with $3.09M a year earlier. Trailing-twelve-month accounts payables was $9.69M. Over 3 fiscal years it compounded at +70.4% a year.
Context
- Accounts payables amounted to 553.9% of revenue in FY2025, up 422.5 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$7M or moves back toward the trailing-twelve-month quarterly average of $2.42M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 11.28M USD
- Year-over-year change
- +37.7%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.28M | +37.7% |
| FY2024 | 2024-12-31 | 8.19M | +1139.2% |
| FY2023 | 2023-12-31 | 661K | -71.0% |
| FY2022 | 2022-12-31 | 2.28M | +416.7% |
| FY2021 | 2021-12-31 | (720K) | — |
Accounts Payables vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 accounts payables of $9.69M is the 2nd largest of the 10 companies compared; the peer median is $443K.
- Its year-over-year change of +1.8% is the 5th highest of 9, against a peer median of +23.6%.
- Accounts payables amounts to 508.8% of revenue for DNTH, versus a peer median of 27.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $81.11M | +53.9% | — | 34.9% | |
| LTM Jun 2026 | $9.69M | +1.8% | +70.4% | 508.8% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $2.18M | +391.0% | — | 29.5% |
| LTM Mar 2026 | $2.06M | -8.4% | +19.4% | 3.8% | |
| FY2025 | $1.62M | +186.9% | +62.8% | 2534.4% | |
| LTM Jun 2026 | $1.12M | -86.9% | +9.5% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $1.01M | +447.4% | — | — |
| LTM Sep 2026 | $540K | -95.9% | -15.7% | 7.6% | |
| LTM Mar 2026 | $443K | -6.7% | +126.3% | 25.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding DNTH) | $443K | +23.6% | +19.4% | 27.2% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.14M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| Deferred Income Tax | 0 | 0 | (661K) | 0 | 0 |
| Stock-Based Compensation | 0 | 1.52M | 2.9M | 12.89M | 22.79M |
| Change in Working Capital | (1.53M) | (1.65M) | 4.86M | (351K) | 16.73M |
| Accounts Receivables | 0 | (4.16M) | 5.16M | 0 | 755K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (720K) | 2.28M | 661K | 8.19M | 11.28M |
| Other Working Capital | (806K) | 229K | (959K) | (8.54M) | 4.69M |
| Other Non-Cash Items | 11.11M | (606K) | (762K) | (6.17M) | (6.67M) |
| Operating Cash Flow | (59.53M) | (29.07M) | (36.86M) | (78.18M) | (129.06M) |
| Capital Expenditures | (1.26M) | (139K) | (110K) | (105K) | (213K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (45.31M) | (61.68M) | (57.42M) | (413.71M) | (435.01M) |
| Sales of Investments | 90M | 2M | 77.79M | 127M | 312.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 43.43M | (59.82M) | 20.25M | (286.81M) | (122.83M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.6M | 0 | 72M | 269.2M | 280.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (3.32M) | 61.57M | (13.58M) | 0 |
| Financing Cash Flow | 89.6M | 96.68M | 133.57M | 255.62M | 280.13M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 73.5M | 7.79M | 116.97M | (109.37M) | 28.23M |
| Free Cash Flow | (60.8M) | (29.21M) | (36.97M) | (78.29M) | (129.27M) |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.